ArticleDigestive diseases and sciences2025
Venture Capital Investments in Gastroenterology from 2012 to 2022: A Window into the Future of Gastroenterology.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Venture-Backed Maternal Health Startups and the Maternal Health Crisis.JAMA health forum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInnovation in gastroenterology (GI) is experiencing several favorable tailwinds. Despite the increasing amount of capital invested in the technology and pharmaceutical sectors of GI, trends in venture capital (VC) funding for this field remain understudied. This is the first analysis of VC investment in GI. PURPOSE: This study aimed to understand the allocation of VC investment in gastroenterology from 2012 to 2022.
methodsWe conducted a retrospective cross-sectional analysis of VC investments in gastroenterology from January 1, 2012, to December 31, 2022. Data was obtained from the PitchBook private capital market database. Investments were categorized broadly into biotechnology, pharmaceuticals, devices and supplies, healthcare services, etc. Total and annual investments were quantified in USD.
resultsFrom 2012 to 2022, $33.34 billion was invested in gastroenterology fields involving 3419 deals with steadily increasing growth, representing a compound annual growth rate of 15.7% between 2012 and 2022. Pharmaceuticals and biotechnology received the largest share (64.61%) followed by healthcare devices and supplies (12.75%). Investments in pharmaceuticals and technology had an outstanding increase from 2019 to 2020 of 141% and has yielded the largest sector in each year throughout 2012 and 2022.
conclusionOur study highlights a notable rise in both the value and volume of VC investments in gastroenterology over time. Particularly noteworthy is the escalating allocation of funds toward biotechnology, pharmaceuticals, and devices which have skyrocketed over the past few years, suggesting a long-term financial interest in the success of gastroenterology innovation. Further research will be needed to explore the impact of VC funding in the field of gastroenterology.
Indexed as
Identifiers
40237909What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.